Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConfIdeS: Imlifidase vs Standard of Care in Highly Sensitized Kidney Transplant Patients
NCT04935177Phase 3Completed
- Sponsor
- Hansa Biopharma
- Start
- Oct 2021
- Primary completion
- Jun 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlifidase in kidney transplantation (2 arms), sponsored by Hansa Biopharma. Primary endpoint: Estimated Glomerular Filtration Rate at 12 months. Started Oct 2021; status: completed.
02
Drugs
imlifidase
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT04935177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935177.